FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated schwannomas

Journal of Biological Chemistry

Volumn 288, Issue 40, 2013, Pages 29105-29114

  Licciulli, Silvia ^a   Maksimoska, Jasna ^b   Zhou, Chun ^b   Troutman, Scott ^a   Kota, Smitha ^a   Liu, Qin ^b   Duron, Sergio ^c   Campbell, David ^c   Chernoff, Jonathan ^d   Field, Jeffrey ^e   Marmorstein, Ronen ^b   Kissil, Joseph L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b WISTAR INSTITUTE   (United States)

^c Afraxis   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMORS; HIGH SPECIFICITY; NEUROFIBROMATOSIS; P-21 ACTIVATED KINASE; POTENT INHIBITOR; SMALL MOLECULE INHIBITOR; TUMORIGENESIS;

BIOCHEMISTRY; BIOLOGY;

SCAFFOLDS;

ADENOSINE TRIPHOSPHATE; FRAX 597; P21 ACTIVATED KINASE; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE 2; PROTEIN KINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SPECIFICITY; EMBRYO; GENE; GENE SILENCING; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MOUSE; NEURILEMOMA; NEUROFIBROMATOSIS; NONHUMAN; PAK1 GENE; PAK2 GENE; PRIORITY JOURNAL; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION;

ENZYME INHIBITORS; MERLIN; NF2; P21-ACTIVATED KINASE; PROTEIN KINASES; SCHWANN CELLS; SIGNAL TRANSDUCTION; SMALL MOLECULES;

ANIMALS; CARCINOGENESIS; CATALYTIC DOMAIN; CELL PROLIFERATION; DRUG DISCOVERY; HUMANS; MICE; MODELS, MOLECULAR; NEURILEMMOMA; NEUROFIBROMATOSIS 2; P21-ACTIVATED KINASES; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINES; PYRIMIDINONES; SMALL MOLECULE LIBRARIES;

EID: 84885117132     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.510933     Document Type: Article

References (49)

1. Zhao, Z. S., and Manser, E. (2012) PAK family kinases: Physiological roles and regulation. Cell Logist. 2, 59-68
2. Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70, 401-410
3. Nobes, C. D., and Hall, A. (1995) Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81, 53-62
4. Ye, D. Z., and Field, J. (2012) PAK signaling in cancer. Cell Logist 2, 105-116
5. Molli, P. R., Li, D. Q., Murray, B. W., Rayala, S. K., and Kumar, R. (2009) PAK signaling in oncogenesis. Oncogene 28, 2545-2555
6. Dummler, B., Ohshiro, K., Kumar, R., and Field, J. (2009) Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 28, 51-63
7. Balasenthil, S., Sahin, A. A., Barnes, C. J., Wang, R. A., Pestell, R. G., Vadlamudi, R. K., and Kumar, R. (2004) p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J. Biol. Chem. 279, 1422-1428
8. Ong, C. C., Jubb, A. M., Haverty, P. M., Zhou, W., Tran, V., Truong, T., Turley, H., O'Brien, T., Vucic, D., Harris, A. L., Belvin, M., Friedman, L. S., Blackwood, E. M., Koeppen, H., and Hoeflich, K. P. (2011) Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 108, 7177-7182
9. Wang, R. A., Zhang, H., Balasenthil, S., Medina, D., and Kumar, R. (2006) PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 25, 2931-2936
10. Vadlamudi, R. K., Adam, L., Wang, R. A., Mandal, M., Nguyen, D., Sahin, A., Chernoff, J., Hung, M. C., and Kumar, R. (2000) Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J. Biol. Chem. 275, 36238-36244
11. Shrestha, Y., Schafer, E. J., Boehm, J. S., Thomas, S. R., He, F., Du, J., Wang, S., Barretina, J., Weir, B. A., Zhao, J. J., Polyak, K., Golub, T. R., Beroukhim, R., and Hahn, W. C. (2011) Pak1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene 31, 3397-3408
12. Adam, L., Vadlamudi, R., Mandal, M., Chernoff, J., and Kumar, R. (2000) Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J. Biol. Chem. 275, 12041-12050
13. Adam, L., Vadlamudi, R., Kondapaka, S. B., Chernoff, J., Mendelsohn, J., and Kumar, R. (1998) Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J. Biol. Chem. 273, 28238-28246
14. Li, Q., Mullins, S. R., Sloane, B. F., and Mattingly, R. R. (2008) p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia 10, 314-329
15. Arias-Romero, L. E., Villamar-Cruz, O., Huang, M., Hoeflich, K. P., and Chernoff, J. (2013) Pak1 kinase links ErbB2 to-catenin in transformation of breast epithelial cells. Cancer Res. 73, 3671-3682
16. Gerber, P. A., Antal, A. S., Neumann, N. J., Homey, B., Matuschek, C., Peiper, M., Budach, W., and Bölke, E. (2009) Neurofibromatosis. Eur. J. Med. Res. 14, 102-105
17. Tang, Y., Marwaha, S., Rutkowski, J. L., Tennekoon, G. I., Phillips, P. C., and Field, J. (1998) A role for Pak protein kinases in Schwann cell transformation. Proc. Natl. Acad. Sci. U.S.A. 95, 5139-5144
18. Yang, F. C., Ingram, D. A., Chen, S., Hingtgen, C. M., Ratner, N., Monk, K. R., Clegg, T., White, H., Mead, L., Wenning, M. J., Williams, D. A., Kapur, R., Atkinson, S. J., and Clapp, D. W. (2003) Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1-/-mast cells. J. Clin. Invest. 112, 1851-1861
19. Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K., and Parada, L. F. (2002) Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296, 920-922
20. Yang, F. C., Ingram, D. A., Chen, S., Zhu, Y., Yuan, J., Li, X., Yang, X., Knowles, S., Horn, W., Li, Y., Zhang, S., Yang, Y., Vakili, S. T., Yu, M., Burns, D., Robertson, K., Hutchins, G., Parada, L. F., and Clapp, D. W. (2008) Nf1-dependent tumors require a microenvironment containing Nf1-/- and c-kit-dependent bone marrow. Cell 135, 437-448
21. McDaniel, A. S., Allen, J. D., Park, S. J., Jaffer, Z. M., Michels, E. G., Burgin, S. J., Chen, S., Bessler, W. K., Hofmann, C., Ingram, D. A., Chernoff, J., and Clapp, D. W. (2008) Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1-/- mast cells. Blood 112, 4646-4654
22. Stamenkovic, I., and Yu, Q. (2010) Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr. Protein Pept. Sci. 11, 471-484
23. Nakai, Y., Zheng, Y., MacCollin, M., and Ratner, N. (2006) Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. J. Neurosci. 26, 3390-3395
24. Kaempchen, K., Mielke, K., Utermark, T., Langmesser, S., and Hanemann, C. O. (2003) Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum. Mol. Genet. 12, 1211-1221
25. Yi, C., Wilker, E. W., Yaffe, M. B., Stemmer-Rachamimov, A., and Kissil, J. L. (2008) Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res. 68, 7932-7937
26. Flaiz, C., Kaempchen, K., Matthies, C., and Hanemann, C. O. (2007) Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomas. J. Neuropathol. Exp. Neurol. 66, 608-616
27. Wilkes, M. C., Repellin, C. E., Hong, M., Bracamonte, M., Penheiter, S. G., Borg, J. P., and Leof, E. B. (2009) Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-. Dev Cell 16, 433-444
28. Xiao, G. H., Gallagher, R., Shetler, J., Skele, K., Altomare, D. A., Pestell, R. G., Jhanwar, S., and Testa, J. R. (2005) The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol. Cell Biol. 25, 2384-2394
29. Hirokawa, Y., Tikoo, A., Huynh, J., Utermark, T., Hanemann, C. O., Giovannini, M., Xiao, G. H., Testa, J. R., Wood, J., and Maruta, H. (2004) A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J. 10, 20-26
30. Kissil, J. L., Wilker, E. W., Johnson, K. C., Eckman, M. S., Yaffe, M. B., and Jacks, T. (2003) Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol. Cell 12, 841-849
31. Morrison, H., Sperka, T., Manent, J., Giovannini, M., Ponta, H., and Her-rlich, P. (2007) Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res. 67, 520-527
32. Chow, H. Y., Stepanova, D., Koch, J., and Chernoff, J. (2010) p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS One 5, e13791
33. Flaiz, C., Chernoff, J., Ammoun, S., Peterson, J. R., and Hanemann, C. O. (2009) PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp. Neurol. 218, 137-144
34. Otwinowski, Z., and Miner, T. (1997) Methods in Enzymology, pp. 307-326, Elsevier Academic Press, San Diego
35. Maksimoska, J., Feng, L., Harms, K., Yi, C., Kissil, J., Marmorstein, R., and Meggers, E. (2008) Targeting large kinase active site with rigid, bulky, octahedral ruthenium complexes. J. Am. Chem. Soc. 130, 15764-15765
36. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D. Biol. Crystallogr 53, 240-255
37. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol. Crystallogr 60, 2126-2132
38. Maksimoska, J., Feng, L., Harms, K., Yi, C., Kissil, J., Marmorstein, R., and Meggers, E. (2008) Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J. Am. Chem. Soc. 130, 15764-15765
39. Blanck, S., Maksimoska, J., Baumeister, J., Harms, K., Marmorstein, R., and Meggers, E. (2012) The art of filling protein pockets efficiently with octahedral metal complexes. Angew Chem. Int. Ed. Engl. 51, 5244-5246
40. Eswaran, J., Lee, W. H., Debreczeni, J. E., Filippakopoulos, P., Turnbull, A., Fedorov, O., Deacon, S. W., Peterson, J. R., and Knapp, S. (2007) Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 15, 201-213
41. Knowles, P. P., Murray-Rust, J., Kjaer, S., Scott, R. P., Hanrahan, S., Santoro, M., Ibáñez, C. F., and McDonald, N. Q. (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 281, 33577-33587
42. Saydam, O., Ozdener, G. B., Senol, O., Mizrak, A., Prabhakar, S., Stemmer-Rachamimov, A. O., Breakefield, X. O., and Brenner, G. J. (2011) A novel imaging-compatible sciatic nerve schwannoma model. J. Neurosci. Methods 195, 75-77
43. Wong, H. K., Lahdenranta, J., Kamoun, W. S., Chan, A. W., McClatchey, A. I., Plotkin, S. R., Jain, R. K., and di Tomaso, E. (2010) Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 70, 3483-3493
44. Murray, B. W., Guo, C., Piraino, J., Westwick, J. K., Zhang, C., Lamerdin, J., Dagostino, E., Knighton, D., Loi, C. M., Zager, M., Kraynov, E., Popoff, I., Christensen, J. G., Martinez, R., Kephart, S. E., Marakovits, J., Karlicek, S., Bergqvist, S., and Smeal, T. (2010) Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 107, 9446-9451
45. Chow, H. Y., Jubb, A. M., Koch, J. N., Jaffer, Z. M., Stepanova, D., Campbell, D. A., Duron, S. G., O'Farrell, M., Cai, K. Q., Klein-Szanto, A. J., Gutkind, J. S., Hoeflich, K. P., and Chernoff, J. (2012) p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res. 72, 5966-5975
46. Zuccotto, F., Ardini, E., Casale, E., and Angiolini, M. (2010) Through the "gatekeeper door": exploiting the active kinase conformation. J. Med. Chem. 53, 2681-2694
47. Barvian, M., Boschelli, D. H., Cossrow, J., Dobrusin, E., Fattaey, A., Fritsch, A., Fry, D., Harvey, P., Keller, P., Garrett, M., La, F., Leopold, W., Mc-Namara, D., Quin, M., Trumpp-Kallmeyer, S., Toogood, P., Wu, Z., and Zhang, E. (2000) Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 43, 4606-4616
48. VanderWel, S. N., Harvey, P. J., McNamara, D. J., Repine, J. T., Keller, P. R., Quin, J., 3rd, Booth, R. J., Elliott, W. L., Dobrusin, E. M., Fry, D. W., and Toogood, P. L. (2005) Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. J. Med. Chem. 48, 2371-2387
49. Lu, H., and Schulze-Gahmen, U. (2006) Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. J. Med. Chem. 49, 3826-3831